Absci Co. (NASDAQ:ABSI – Get Rating)’s stock price traded up 1% during mid-day trading on Tuesday . The stock traded as high as $3.25 and last traded at $3.12. 466,859 shares changed hands during mid-day trading, a decline of 0% from the average session volume of 468,491 shares. The stock had previously closed at $3.09.
Absci Price Performance
The business’s 50-day moving average price is $2.48 and its two-hundred day moving average price is $3.12. The firm has a market cap of $288.27 million, a price-to-earnings ratio of -2.54 and a beta of 0.62. The company has a debt-to-equity ratio of 0.03, a current ratio of 6.71 and a quick ratio of 6.71.
Absci (NASDAQ:ABSI – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The company had revenue of $2.37 million during the quarter, compared to analysts’ expectations of $1.79 million. Absci had a negative return on equity of 33.62% and a negative net margin of 1,960.28%. On average, research analysts forecast that Absci Co. will post -1.13 EPS for the current fiscal year.
Institutional Trading of Absci
About Absci
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.
Read More
- Get a free copy of the StockNews.com research report on Absci (ABSI)
- 3 Retail Stocks Ringing the Register in 2023
- When Will Crane Holdings Take Flight?
- Is It Time To Get Aggressive With Defense Stocks?
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.